Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

Project description

Revealing non-genetic determinants of cancer cell plasticity in gene-related cancers

The ability of cancer cells to change their molecular and phenotypic identities contributes to metastases and treatment resistance. Stopping or reversing this could open a new pathway to cancer treatment. Paediatric tumours exhibit remarkable plasticity. Using organoid technology, single-cell genomics and lineage tracing approaches, the consortium of the ERC-funded MaturingKidsCancer project recently showed that paediatric cancers exhibit robust yet pharmacologically reversible plasticity at the level of the epigenome. MaturingKidsCancer will use single-cell transcriptomics and epigenomics, its unique paediatric cancer organoids and patient-derived tissues to uncover fundamental principles governing cancer cell plasticity. Outcomes will support new methods and strategies for cancer therapy.

Objective

Introduction
Cancer cell plasticity, the ability of cancer cells to change their identity, enables tumors to adapt to hostile environments, aiding metastasis and resistance to treatments. Hence, plasticity is a major unsolved problem frustrating effective treatment. Unraveling the mechanisms underlying cancer cell plasticity is crucial to establish new avenues for cancer therapy. In contrast to adult cancers, many pediatric tumors are driven by a single genetic alteration that fuels their aggressive nature through remarkable plasticity. Despite their differences, pediatric cancers offer a unique platform to investigate cancer cell plasticity due to their genetically clear characteristics. I hypothesize that plasticity can be reversed to differentiate tumor cells and “mature cancer”.

Goal
Building upon previous ERC-StG funding, we have successfully utilized organoid technology, single-cell genomics, and lineage tracing approaches to uncover the origins of various pediatric cancers. Our findings revealed that these cancers exhibit robust yet pharmacologically reversible plasticity at the level of the epigenome. The goal of this proposal is to reverse cell state changes during tumorigenesis to “mature cancer”.

Approach
We will I) apply advanced (spatial) single-cell transcriptomics and epigenomics approaches to a unique cohort of pediatric tumors and metastases to map out cell state changes during disease progression, II) utilize our unique pediatric cancer organoids to interrogate and target hierarchical trajectories with the aim to mature cancer, and III) screen the enhancer-ome to identify non-genetic determinants of cancer cell plasticity.

Innovation
Integrating these cutting-edge technologies on patient-derived tissues and organoids will uncover fundamental principles governing cancer cell plasticity. The research will pioneer innovative methodologies and reveal strategies for identifying cancer maturation targets, advancing cancer therapy research

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-COG

See all projects funded under this call

Host institution

PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV
Net EU contribution
€ 2 000 000,00
Total cost
€ 2 000 000,00

Beneficiaries (1)